1227 results about "Pharmaceutical technology" patented technology

The invention provides a medical wholesale and retail comprehensive service method and system based on the Internet, and relates to the technical field of medicines.The medical wholesale and retail comprehensive service method comprises the steps that a hospital HIS system is docked in real time through an API, and electronic prescription data are collected; the collected electronic prescription data is connected with a medicine wholesale enterprise ERP system, the inventory state, batch number and validity period information of each medicine are obtained, and inventory information is obtained. According to the invention, through real-time connection of the hospital HIS system, the drug wholesale enterprise ERP system and the retail terminal POS system, inventory information can be obtained and dynamic management can be carried out. The real-time data updating not only improves the inventory turnover rate, but also can automatically warn the medicines close to the expiration date, and reduces the loss of the expired medicines. The LSTM neural network is adopted to predict the drug demand, and the replenishment suggestion is generated in combination with the linear programming model, so that the replenishment process can be optimized while the operation cost is minimized, and sufficient and efficient inventory is ensured.

The invention provides a preparation method of medicinal liquor and application of the medicinal liquor in preparation of analgesic and anti-inflammatory products, and relates to the technical field of medicines. The preparation method comprises the following steps: (1) crushing; (2) extracting; (3) standing and separating; and (4) freezing and filtering to obtain the medicinal liquor. In the preparation process, traditional Chinese medicine components are extracted through the steps of batch crushing, mixed extraction, standing, freezing and separation of supernate and suspension in different separation modes to obtain the medicinal liquor, and the medicinal liquor can better inhibit pain caused by thermal stimulation and chemical substances and has a better analgesic effect; the traditional Chinese medicine composition can inhibit capillary permeability increase caused by acetic acid, has a better effect of inhibiting inflammation exudation, and has remarkable analgesic and anti-inflammatory effects.

The utility model discloses a double-butterfly-valve sterile medicine transfer system, and relates to the technical field of pharmacy. Comprising a turnover medicine storage tank, a driving butterfly valve, a driven butterfly valve, a powder storage tank and a sterile liquid medicine storage bag, a discharging port of the turnover medicine storage tank is connected with the driving butterfly valve through a first connecting piece, and the driving butterfly valve is connected with the driven butterfly valve through a second connecting piece; the passive butterfly valve is connected with a feeding port of a powder storage tank through a third connecting piece, a first diaphragm valve is arranged at a discharging port of the powder storage tank, and the discharging port of the powder storage tank is connected with a sterile liquid medicine storage bag; by adopting the design of double butterfly valves, sterile connection is established between the turnover medicine storage tank and the powder storage tank, the reliability of hoop connection is high, the structure is simple, the operation complexity is low, the universality is high, the flexibility is high, and the cost is low.

The invention relates to an oral mucosa repairing medicine and a preparation method thereof, and belongs to the technical field of medicines, the medicine comprises barnacle peptide, salivary lactobacillus, resveratrol, a biphasic adhesion matrix, hydroxyapatite, vitamin B family and other components. The preparation method comprises the following steps: sequentially carrying out enzymolysis on barnacle gooseneck by pepsin and lumbrukinase to obtain barnacle peptide. The double-phase adhesion matrix comprises a water-phase matrix, an oil-phase matrix and lecithin; the water-phase matrix contains a chondroitin sulfate-chitosan quaternary ammonium salt compound, sodium alginate and other components; the oil-phase matrix comprises sesame oil, beeswax, a polylactic acid-glycolic acid copolymer and the like. According to the invention, barnacle peptide and salivary lactobacillus are prepared by adopting a special method and are matched with resveratrol for use, so that multi-target and multi-path promotion of oral mucosa repair can be realized; the chondroitin sulfate-chitosan quaternary ammonium salt compound is prepared through electrostatic and physical embedding, the chondroitin sulfate-chitosan quaternary ammonium salt compound is matched with other components to prepare the biphasic adhesion matrix, the biocompatibility is good, the adhesion is high, and the action time of a sustained-release drug is well prolonged.

The present invention relates to the field of pharmaceutical technology, and more particularly to the use of Morinda officinalis polysaccharide in preparing a product for improving renal fibrosis. The preparation method of the Morinda officinalis polysaccharide comprises the following steps: (1) extracting Morinda officinalis from water, filtering, and obtaining a supernatant; (2) subjecting the supernatant to alcohol precipitation to obtain a precipitate; and (3) dialyzing and removing protein from the precipitate. The Morinda officinalis polysaccharide has a significant therapeutic effect in improving renal fibrosis.

The invention belongs to the technical field of medicines, and particularly relates to application of Comput-8 in preparation of a product for relieving or treating retina degeneration induced by blue light damage. It is found for the first time that Compond-8 has a protection effect on retina rod cells and cone cells induced by blue light damage, the cilia length, density and membrane disc thickness of the cone cells and the rod cells can be increased, the thickness of a retina outer nuclear layer can be increased, photoreceptor cell damage caused by blue light exposure can be remarkably improved, and the photoreceptor cell damage can be remarkably reduced. The retina degeneration caused by blue light injury can be relieved or treated, and a new thought and means are provided for treatment of the retina degeneration induced by the blue light injury.

The invention relates to the technical field of medicines. The invention provides sapropterin hydrochloride powder and a preparation method thereof. The sapropterin hydrochloride powder comprises the following components in percentage by mass: 15%-30% of sapropterin hydrochloride, 50%-60% of a filler, 8%-18% of a cosolvent, 3%-6% of a lubricant, 1%-3% of a flavoring agent and 0.1%-1% of an antioxidant. The sapropterin hydrochloride powder prepared by adopting the technical scheme has the characteristics of good solubility, high stability, high bioavailability and convenience in taking.

The invention relates to the technical field of medicines, in particular to application of an active ingredient xanthohumol (XAN) derived from a traditional Chinese medicine humulus lupulus in preparation of medicines for reducing uric acid and resisting gout, and the xanthohumol (XAN) can be prepared into various oral preparations, injection preparations and external preparations with the assistance of pharmaceutically acceptable auxiliary materials and has good development and application prospects. The inventor finds that the xanthohumol has relatively strong effects of reducing blood uric acid, resisting inflammation, resisting bone damage and the like, and the mechanism of the effect of reducing the blood uric acid is that the activity of xanthine oxidase is inhibited so as to reduce the generation of uric acid, and the renal function of an organism is improved so as to enhance uric acid excretion; according to the anti-inflammatory effect, the inflammatory reaction is relieved mainly by down-regulating the levels of inflammatory factors such as IL-1beta, IL-6, TNF alpha and PEG2; the mechanism for resisting gout bone damage is realized through the fact that RANKL / OPG / RANK signal pathway participates in bone metabolism regulation.

This invention relates to the field of pharmaceutical technology, specifically to a substituted pyridotriazole compound, its preparation method, and its uses. This specification discloses a substituted pyridotriazole compound that inhibits RIPK1 and / or MLK, as well as its pharmaceutically acceptable salts, stereoisomers, solvent compounds, or prodrugs. The compound is shown in formula (I), where the definitions of each group are detailed in the specification. Furthermore, this invention also discloses pharmaceutical compositions comprising this compound and their use in the preparation of medicaments for treating RIPK1-related diseases or conditions.

The invention relates to an algin sulfate (PMGS) patch as well as a preparation method and application thereof, and belongs to the technical field of medicines. According to the application, the fucoidan polysaccharide sulfate (PMGS) is used as a main raw material of the microneedle for the first time, the needle tip is completely composed of PMGS, the PMGS plays a role in medicine and adjuvant integration, on one hand, the PMGS is used as a needle tip matrix to provide enough mechanical strength to pierce warts and surrounding skin and is more suitable for related warts with obvious skin thickening, and on the other hand, the PMGS is diffused and released at the position where viruses are located, so that the effect of preventing and treating warts is achieved. The skin wart treatment effect is achieved by preventing virus from entering and enhancing skin immunity, compared with a previous authorized patent scheme, the problems that PMGS as macromolecular polysaccharide enters the skin and is insufficient in absorption are solved in a microneedle mode, PMGS can be directly delivered to basal layer cells where HPV is located, and fixed-point drug delivery is achieved.

The utility model discloses a tablet detecting and sorting device, and relates to the technical field of pharmacy. Comprising a feeding mechanism used for providing tablets, a separating mechanism used for outputting the tablets one by one, a conveying mechanism used for conveying the tablets in a matrix mode, a machining head used for machining the tablets, a camera used for detecting the appearances of the tablets, a defective product box used for collecting the tablets with the unqualified appearances, and a supplementing mechanism used for supplementing the qualified tablets. And the negative pressure discharging belt is used for matrix type discharging. According to the utility model, manual operation is not needed, high-efficiency and high-accuracy detection and sorting can be carried out on tablets in a full-automatic manner, the possibility that inferior-quality products are mixed into qualified products is greatly reduced, the qualified products can be conveyed to the downstream in a tidy and matrix arrangement manner, the qualified products can be directly connected with various packaging devices for use, and the applicability is stronger.

The invention belongs to the technical field of biochemical pharmacy, and particularly relates to a bezoar intermediate and a preparation method of bezoar. The preparation method comprises the following steps: mixing preparation raw materials and biochemical reaction liquid to obtain a mixed raw material solution; the preparation raw materials comprise bilirubin, organic active raw materials and vitamins, the biochemical reaction liquid is sterile purified water, and the bilirubin comprises bilirubin or biliverdin; and reacting the mixed raw material solution to obtain the bezoar intermediate. The content of combined bilirubin in the bezoar intermediate prepared by the preparation method provided by the invention is 75%-85%, the content of combined biliverdin is 73%-83%, and the yield is 83%-87%. According to the method, the poisoning and destroying effects of mycotoxin on the content, the yield, the biological activity and the oxidation resistance of the bezoar intermediate are effectively eliminated. The content, the yield, the oxidation resistance and the biological activity of the bezoar intermediate are greatly improved, the performance is stable, and the quality of bezoar is ensured.

The invention discloses an application of isorhamnetin in preparation of an anti-myocardial fibrosis medicine, and belongs to the technical field of medicines. The invention proposes that the isorhamnetin can effectively reduce myocardial tissue collagen deposition for the first time, and the medical application of the isorhamnetin is expanded. The isorhamnetin is used as the anti-myocardial fibrosis medicine, can effectively relieve the increase of mRNA expression levels of alpha-SMA, COL-1, COL-3, p53, PAI-1, IL-1beta and IL-6, and has the function of retarding myocardial fibrosis. The isorhamnetin is used as the active component of the anti-myocardial fibrosis medicine, the safety is high, the side effect is small, a novel anti-myocardial fibrosis treatment strategy is provided, and the application blank of the isorhamnetin in the field is filled.

The invention belongs to the technical field of medicines, and particularly relates to an HPLC (High Performance Liquid Chromatography) detection method for LXH-1211 and impurities thereof. Respectively injecting the control solution, the impurity control solution, the blank solution and the test solution into a liquid chromatograph, recording chromatograms, calculating the content of LXH-1211 in the test solution according to a peak area normalization method, and calculating the content of impurities in the test solution according to a peak area according to an external standard method; wherein the impurities are one or more of ZZ1, ZZ2, ZZ3 or ZZ4. The method is good in reproducibility and stability and excellent in precision.

The invention provides a cyclodextrin-based nano anti-tumor medicine preparation as well as a preparation method and application thereof, and belongs to the technical field of medicines. The preparation method comprises the following steps: preparing a graphene quantum dot deposition gold nanocage modified by a silane coupling agent, carrying out a Schiff base reaction on the graphene quantum dot deposition gold nanocage and aldehyde substituted-beta-cyclodextrin to prepare a composite carrier, and coating a targeted peptide-drug compound through the reaction, thereby preparing the cyclodextrin-based nano anti-tumor drug preparation. According to the cyclodextrin-based nano anti-tumor medicine preparation prepared by the invention, the anti-tumor medicine effect is obviously improved, meanwhile, the medicine resistance of the medicine can be reversed, the damage to normal tissues is reduced, the use amount of the medicine is reduced, the side effect after the medicine is used is reduced, the compliance of a patient is improved, and meanwhile, the stability and biocompatibility of the medicine can be improved; wide application prospects are realized.

The invention belongs to the technical field of medicines, and relates to chemical synthesis, in particular to a synthesis process of retinoic acid silane ester. The invention discloses a synthesis process of retinoic acid silane ester. The retinoic acid silane ester is prepared by carrying out nucleophilic reaction on retinoic acid and halomethyltrimethylsilane in the presence of alkali. According to the invention, the raw materials retinoic acid, chloromethane trimethylsilane and cesium carbonate are added into the solvent, the reaction temperature is controlled, after the reaction is finished, the product is obtained through post-treatment crystallization, and according to the synthesis process, the maximum product yield is about 90%.

The invention belongs to the technical field of medicines, and provides a compound for inhibiting virus replication and application of the compound in preparation of a medicine for resisting feline infectious peritonitis virus (FIPV). The number of the compounds provided by the invention is 10, and the 10 compounds have obvious inhibiting and blocking effects on a 1-bit ribosome frameshift process of the FIPV, and can effectively inhibit the replication and proliferation of the FIPV. The ten compounds can be used for treating and preventing feline infectious peritonitis diseases caused by FIPV infection; the compound disclosed by the invention can be used for preparing anti-FIPV medicines and medicines for treating and preventing feline infectious peritonitis diseases caused by FIPV infection, and has a wide application prospect.

The invention provides a traditional Chinese medicine preparation for treating allergic rhinitis and a preparation method thereof, and relates to the technical field of traditional Chinese medicine pharmacy, the traditional Chinese medicine preparation is prepared from radix asteris, schizonepeta spike, cynanchum paniculatum, perillaseed, spina gleditsiae, cottonrose hibiscus leaf, magnolia flower, semen brassicae, cortex lycii radicis, dendrobe, oroxylum indicum and rhodomyrtus tomentosa; an in-vitro experiment shows that the traditional Chinese medicine preparation can remarkably inhibit the activity of hyaluronidase, also can inhibit the release of beta-HEX in an RBL-2H3 cell degranulation model, reduces the HIS level in a cell supernatant, and effectively improves the morphological abnormality caused by degranulation of RBL-2H3 cells; in-vivo experiments show that the traditional Chinese medicine preparation can significantly reduce behavioral scores of mice suffering from allergic rhinitis, inhibit expression of inflammatory factors TNF-alpha, serum Ig E and OVE-sIg E levels and HA concentration, reduce histopathologic changes caused by allergic rhinitis, effectively repair immune injuries of nasal mucosa of the mice and improve the curative effect of the mice. And a safe and effective new strategy is provided for the treatment of allergic rhinitis.

The invention belongs to the technical field of biology and new medicine, and discloses a method for constructing a myxobacteria expression chassis with genetic stability and application of the myxobacteria expression chassis. Through gene deletion and overexpression analysis, it is verified that the spontaneous mutation rate of a strain can be reduced by deletion of a TLS pathway and overexpression of RecA, and a myxobacteria strain 2K7 with genetic stability is further constructed on the basis. The spontaneous mutation rate of the new strain is reduced by 11.5 times, and the transformation capability of growth plasmids of the strain is obviously improved. According to the research, the genetic stability of the myxobacteria is improved for the first time through a repair way after modification and replication, and the research method and the research result are innovative.

The invention relates to application of visceral odorobacter and outer membrane vesicles thereof in preparation of drugs for treating acute lung injury, and relates to the technical field of drugs. The modeling medicine lipopolysaccharide is applied to a mouse individual in a nasal dripping mode, the administration mode is that each mouse is administered once a day, and intragastric administration is carried out once a day after modeling is carried out for two days and lasts for 7 days. Experiments prove that visceral odorobacter and outer membrane vesicles of the visceral odorobacter reduce the number of M1 type alveolar macrophages by down-regulating proinflammatory factors IL-6, TNF-alpha and IL-1beta in lung tissues and inhibiting three proinflammatory factors IL-6, TNF-alpha and IL-1beta in serum, so that the effect of remarkably reversing acute lung injury is achieved. The visceral odor bacilli and the outer membrane vesicles thereof are used for preventing and treating the acute lung injury, and a new method and means are provided for clinically treating the acute lung injury.

The invention belongs to the technical field of medicines, and particularly relates to a preparation method of a heart failure treatment drug viriciguat. Specifically, a specific starting raw material is adopted, dimethyl carbonate is used as an acylation reagent, a proper Lewis acid is used for catalysis, and the vericiguat is synthesized under a solvent-free condition. The process avoids the defects of high toxicity, strong corrosivity, difficulty in process condition control, high cost and the like caused by acylation by using methyl chloroformate or dimethyl dicarbonate in the final reaction of the existing Velciguat synthesis process route. The preparation method can be used for preparing high-purity Velciguat with high yield, and the used reagent is low in toxicity, simple and convenient to operate, green, environment-friendly, low in cost and suitable for industrial large-scale production. # imgabs0 #

The invention discloses melogabalin besylate tablets and a preparation method thereof, and relates to the technical field of medicines. The melogabalin besylate tablet is prepared from melogabalin besylate, a filling agent, a disintegrating agent, a stabilizing agent, a lubricating agent and an antioxidant composition, the antioxidant composition comprises tartaric acid and squalene. The preparation process is optimized, a uniform and stable solid dispersion is prepared by means of a hot melt extrusion process, and it is guaranteed that active raw materials and the antioxidant are uniformly mixed; the antioxidant composition with compatibility of tartaric acid and squalene is screened, and the stability of the antioxidant in the long-term storage process is remarkably improved.

The invention provides application of tipirfarb in reversing osimertinib drug resistance, and relates to the technical field of medicines. The research of the inventor finds that the high expression of the MAST1 protein induces the targeted drug resistance of lung cancer, and the MAST1 protein can be used as an anti-drug-resistance action target. A new MAST1 inhibitor tipirfarb is obtained through virtual screening, and the antitumor activity of osimertinib on drug-resistant cells can be enhanced. The invention lays a foundation for subsequent development of an MAST1-targeted anti-drug-resistance strategy, provides brand new anti-drug-resistance targets and candidate molecules for targeted therapy of lung cancer, and has clinical value.

The invention discloses a method for detecting related substances in imaric acid dihydrochloride by HPLC (High Performance Liquid Chromatography), and belongs to the technical field of chemical engineering and pharmacy, the related substances in the imaric acid dihydrochloride are detected by high performance liquid chromatography, a phosphate buffer solution (0.05 mol / L of monopotassium phosphate solution, and pH adjusted to 2.5 by phosphoric acid) is used as a mobile phase A, acetonitrile is used as a mobile phase B, gradient elution is carried out, the flow rate is 1.0 ml / min, the detection wavelength is 250nm, and the detection wavelength is 250nm. The column temperature is 40 DEG C, and the detection wavelength is 235nm; the method can be used for effectively separating and quantitatively detecting imatamide, demethylated imaric acid dihydrochloride, ortho-imaric acid, meta-imaric acid, p-hydroxymethyl benzamide, an intermediate B, p-hydroxymethyl benzoic acid, an imaric acid dimer, p-cyanobenzyl alcohol, p-chloromethyl benzamide, p-toluic acid and p-chloromethyl benzoic acid in the imaric acid dihydrochloride. The method disclosed by the invention is simple and convenient to operate, strong in specificity, high in sensitivity and accuracy, good in linearity and capable of effectively controlling the quality of a p-imaric acid dihydrochloride product.

The invention belongs to the technical field of medicine, particularly relates to application of isodan-leaf emodin in preparation of a CXCL10 inhibitor, and particularly relates to application of the isodan-leaf emodin in treatment of sepsis lung injury, and by establishing a sepsis lung injury model induced by cecum ligation puncture (CLP), the application of the isodan-leaf emodin in preparation of the CXCL10 inhibitor is established. It is proved that the polyphenol monomer drug isodan leaf emodin can significantly improve lung tissue pathological damage, reduce the level of inflammatory factors in lung tissue, inhibit oxidative stress reaction and improve the survival rate of a CLP model. Experiments show that the isodan leaf emodin with the dosage of 25 mg / kg can relieve pulmonary edema and inflammatory response by inhibiting secretion of CXCL10, and a new scheme is provided for treatment of sepsis-related lung injury.

The present invention pertains to the field of pharmaceutical technology. Specifically, the present invention relates to a zinc risedronate micro / nano adjuvant with sustained-release function formed by mineralization of zinc ions and risedronic acid as main components and its use as a vaccine adjuvant. The present invention also relates to a method for preparing zinc risedronate micro / nano adjuvant. The present invention also relates to a chemical composition, vaccine adjuvant and vaccine composition comprising zinc risedronate micro / nano adjuvant. The present invention also relates to a use of zinc risedronate micro / nano adjuvant as a vaccine adjuvant.

The invention relates to the technical field of medicines, in particular to application of triptolide in preparation of a medicine for preventing or treating Alport syndrome. On the basis of a double evidence chain of clinical data and mechanism research, triptolide can be used for preventing and treating the Alport syndrome, an innovative solution is provided for clinical prevention and treatment of the Alport syndrome, and the application prospect is wide.

The invention belongs to the technical field of medicines, and particularly relates to application of indole-3-lactic acid in preparation of medicines for treating diabetes and complications. A db / db mouse is utilized to simulate the pathological process of human diabetes, the db / db mouse is orally administered with indole-3-lactic acid, and after the db / db mouse orally administered with indole-3-lactic acid, the blood glucose and blood fat of the diabetic mouse can be reduced, the cardiac function impairment of the diabetic mouse is improved, and the brain cognitive dysfunction of the diabetic mouse is improved. It is proved that the indole-3-lactic acid has a treatment effect on diabetes and cardiovascular and cerebrovascular complications thereof.

The invention relates to the technical field of medicines, in particular to a preparation method of calcium L-5-methyltetrahydrofolate. According to the method, N-(4-aminobenzoyl)-L-glutamic acid, 2, 4, 5-triamino-6-hydroxypyrimidine sulfate and propane trihalide are adopted as starting raw materials, and tetrahydrofolic acid is synthesized through a one-pot method; compared with synthesis of L-5-methyl calcium tetrahydrofolate by using high-purity folic acid as an initial raw material, the process route does not involve use of chemical reagents such as sodium borohydride, zinc powder and some noble metal catalysts any more, the reaction is easier to control, the cost is lower, the safety is higher, the method is more environmentally friendly, and industrial production is easier to carry out.

This invention belongs to the field of pharmaceutical technology, specifically relating to a quinazoline-azaindole compound, its preparation method, and its application in treating Alzheimer's disease. The quinazoline-azaindole compound of this invention regulates NF-κB by inhibiting DYRK1A. k B. A series of signaling pathways, including PI3k-Akt, achieve anti-neuroinflammatory effects; quinazoline-azaindole compounds can reduce the expression of inflammatory factor-related genes in an LPS-induced BV2 microglial inflammation model, thereby reducing the levels of inflammatory factors in the hippocampus and cortex, alleviating neuronal pathological damage caused by neuroinflammation, and improving cognitive impairment caused by neuroinflammation; in summary, quinazoline compounds inhibit DYRK1A and downregulate NF-κB signaling pathways. k It can reduce the expression and release of inflammatory factors, improve brain tissue pathology, and alleviate cognitive impairment through signaling pathways such as B, and has significant clinical application value.